Abstract
Currently used non-specific immunosuppressive drugs often require intervention in myasthenia gravis (MG) and clinical improvement varies widely. To analyze the therapeutic effect of mycophenolate mofetil (MMF) in experimental autoimmune MG (EAMG), rats were immunized with acetylcholine receptors (AChRs) and subsequently treated with MMF or vehicle. MMF treatment resulted in a significant suppression of anti-rat AChR antibody titers. Interestingly, no abnormalities of neuromuscular transmission and adverse side effects were detected in MMF-treated EAMG animals. Moreover, anti-rat AChR antibody titers correlated to an improvement of clinical outcome. In conclusion, our data suggest that MMF acts as a potent immunosuppressant drug in EAMG.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Action Potentials / drug effects
-
Action Potentials / physiology
-
Action Potentials / radiation effects
-
Analysis of Variance
-
Animals
-
Antibodies / blood
-
Disease Models, Animal
-
Electromyography / methods
-
Female
-
Immunosuppressive Agents / therapeutic use*
-
Muscle Proteins / metabolism
-
Muscle, Skeletal / metabolism
-
Muscle, Skeletal / physiopathology
-
Myasthenia Gravis, Autoimmune, Experimental / blood
-
Myasthenia Gravis, Autoimmune, Experimental / drug therapy*
-
Myasthenia Gravis, Autoimmune, Experimental / etiology
-
Myasthenia Gravis, Autoimmune, Experimental / pathology
-
Mycophenolic Acid / analogs & derivatives*
-
Mycophenolic Acid / therapeutic use
-
Rats
-
Rats, Inbred Lew
-
Receptors, Cholinergic / immunology
-
Receptors, Cholinergic / metabolism
-
Statistics, Nonparametric
-
Time Factors
-
Vesicular Acetylcholine Transport Proteins / metabolism
Substances
-
Antibodies
-
Immunosuppressive Agents
-
Muscle Proteins
-
Receptors, Cholinergic
-
Slc18a3 protein, rat
-
Vesicular Acetylcholine Transport Proteins
-
peripheral membrane protein 43K
-
Mycophenolic Acid